- Nearly all planned REO 033 Part A sites are activated
- Multiple patients are currently enrolled
- Part A targets approximately 60 patients randomized 1:1
- Primary endpoint is objective response rate
- Company expects interim data by year-end 2026 based on evaluable patients enrolled by end of October
- FDA aligned on concept for potential pivotal Part B expansion
The headline and the read are open. The reasons are one free account away, on every story.
One free account opens every story complete, the live board, the 30-day calendar, a watchlist and breaking alerts on your phone. No card. The wire stays free to read.
BORSAPLUSWhy it matters · Bull and bear case · Reaction against SPY and the sector · What to watch
Create a free account · no card